MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$733K
Net Income
-$15,009K
Net Profit Margin
-2047.61%
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
733
0
718
132
Research and development
9,957
11,181
6,588
5,870
General and administrative
6,474
6,665
6,423
6,785
Total operating expenses
16,431
17,846
13,011
12,655
Loss from operations
-15,698
-17,846
-12,293
-12,523
Other income (expense), net
689
858
21,957
365
Gain before provision for income taxes
-15,009
-16,988
9,663
-12,158
Provision for income taxes
0
0
0
0
Net gain
-15,009
-16,988
9,663
-12,158
Basic EPS
0
0
9,538.993
-168.01
Diluted EPS
0
0
9,538.993
-168.01
Basic Average Shares
0
0
1,013
1,250
Diluted Average Shares
0
0
1,013
1,250
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
OVID Income Statement Sankey Diagram
Sankey diagram visualizing OVID income statement for the period
Net gain
-$15,009K
(-220.43%↓ Y/Y)
Gain before
provision for income taxes
-$15,009K
(-220.43%↓ Y/Y)
Other income
(expense), net
$689K
(77.12%↑ Y/Y)
Loss from operations
-$15,698K
(-209.44%↓ Y/Y)
Total revenue
$733K
(-88.31%↓ Y/Y)
Total operating
expenses
$16,431K
(44.83%↑ Y/Y)
Research and development
$9,957K
(54.01%↑ Y/Y)
General and
administrative
$6,474K
(32.66%↑ Y/Y)
Buy us a coffee
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)